

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED

大成生化科技集團有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00809)

PROPOSED AMENDMENTS AND ADOPTION OF THE AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION

This announcement is made by Global Bio-chem Technology Group Company Limited (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company proposes to amend the existing memorandum and articles of association of the Company (the “**Existing M&A**”). Pursuant to the Consultation Conclusions on Listing Regime for Overseas Issuers published by the Stock Exchange in November 2021, the Listing Rules have been amended with effect from 1 January 2022 which requires, among others, listed issuers to adopt a uniform set of 14 “Core Standards” for shareholder protections for issuers. Furthermore, the Company proposes to modernise and provide flexibility to the Company in relation to the conduct of general meetings. As such, the Board proposes to amend the Existing M&A for the purposes of, among others, (i) allowing a general meeting to be held as an electronic meeting or a hybrid meeting; (ii) bringing the memorandum and articles of association of the Company in line with amendments made to the Listing Rules and applicable laws and procedures of the Cayman Islands; (iii) making other house-keeping amendments to clarify certain provisions of the Existing M&A; and (iv) making other amendments to update or modify provisions and/or defined term(s) where the Board considers appropriate in accordance with or to better align with the wordings in the applicable laws of Cayman Islands and the Listing Rules (collectively, the “**Proposed Amendments**”). Details of the Proposed Amendments will be set out in the circular to be despatched to the shareholders of the Company (the “**Shareholders**”) in due course.

At the upcoming annual general meeting of the Company (the “**2023 AGM**”), a special resolution will be proposed for the Shareholders to consider and, if thought fit, approve the Proposed Amendments and the adoption of the new set of amended and restated memorandum and articles of association (the “**Amended and Restated M&A**”) incorporating the Proposed Amendments.

A circular containing, among other things, further details of the Proposed Amendments and the adoption of the Amended and Restated M&A, together with a notice of the 2023 AGM, will be despatched to the Shareholders in due course.

By order of the Board
Global Bio-chem Technology Group Company Limited
Yang Jian
Chairman

Hong Kong, 14 April 2023

As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Yang Jian and Mr. Wang Guicheng; one non-executive Director, namely, Mr. Gao Dongsheng; and three independent non-executive Directors, namely Ms. Dong Hongxia, Mr. Ng Kwok Pong and Mr. Yeung Kit Lam.

** For identification purposes only*